Showing 718 articles tagged

New Movember funds will turn treatment research into clinical reality

1 Dec 2015

Our £1.5m of Movember Foundation Translational Awards will ensure four groundbreaking projects make it through the labs and into clinical trials.

Extra NHS funding announced for new drugs and cancer diagnosis in England

24 Nov 2015

Prostate Cancer UK welcomes today's government announcement of billions in additional funds for NHS England to spend on drugs and diagnosis up to 2020-21.

A year of Excellence for our new research centres

23 Nov 2015

It's almost a year since our Movember Centres of Excellence opened their doors for business. Here’s a roundup of what's happened so far.

On the frontline: the health professionals doing mo' with your money

23 Nov 2015

Meet the vital clinical staff we fund, with support from Movember, to help smooth and improve the process of treatment for men with prostate cancer.

NHS England and NICE join forces to open consultation on access to cancer drugs

20 Nov 2015

NHS England and NICE have published a document outlining how they plan to work together to reform access to cancer drugs in England. What does it mean for men? We’re on the case to find out.

Lads Night In winners 'shocked' to be dealt trip to Bahamas

19 Nov 2015

Glaswegian Alan MacVicar will be taking four friends to play cards on the Caribbean island after scooping PokerStars' prize holiday in our September fundraiser.

Stockholm study heralds a major change in assessing prostate cancer risk

11 Nov 2015

BLOG: Sophie Lutter explains the full story behind the 'extremely promising' results from a Swedish trial of a new prostate cancer screening programme.

New screening programme proves more reliable than PSA alone in Stockholm trial

10 Nov 2015

Number of biopsies reduced by 27 per cent without compromising patients' safety find Swedish trials of a potentially game-changing screening programme for prostate cancer.

Blood test can measure abiraterone's effectiveness, new trial reveals

4 Nov 2015

Researchers find DNA in blood samples can determine when life-prolonging drug abiraterone has stopped working in men with advanced prostate cancer.